REV1

Across TCGA pan-cancer cohorts, REV1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated REV1 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher REV1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated REV1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

UCEC, GBM, and LUAD are the cancer types where REV1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.338	1.000	.027	4	view →
GBM	DFS	Median	All	0.207	0.593	.010	3	view →
LUAD	DFS	Tertile	All	1.000	0.205	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

REV1–UCEC (OS)

Open the UCEC breakdown →